AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$DXCM

SAYER KEVIN R sold $2.4M of DXCM

SAYER KEVIN R (Executive Chair) sold 26,756 shares of DEXCOM INC (DXCM) at an average of $90.01 ($89.71–$91.41, $2.41M total) across 3 trades on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SAYER KEVIN R
Published Aug 24, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DXCM
Bearish
medium confidence
Mentioned
$DXCM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMBearishLow
01

Why it matters

The disclosed sale adds new information for traders evaluating Dexcom's short‑term outlook.

02

Market read

Insider sale is a primary disclosure that may influence short‑term price action.

03

What to watch

Potential upcoming product announcements or earnings could offset the sale impact.

Relevance 5/10Novelty 5/10Timing: filing disclosed on 2026‑08‑24

Background

Form 4 filings provide the first public record of insider transactions.

Company-level read

Ticker impact

$DXCMBearishMedium confidence
Context

Executive Chair Kevin Sayer sold 26,756 shares for $2.4M via a 10b5‑1 plan on 2026‑08‑20.

Expected impact

Potential modest dip in DXCM price over the next few days.

Evidence & confidence

Sale size is notable for an executive but not large enough to drive a major move; market may price in a slight bearish bias.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

No significant regional effect.

Global

Limited to investors tracking Dexcom.

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • Company
    Dexcom Inc.

    US‑listed medical device maker (ticker DXCM).

  • Individual
    Kevin Sayer

    Executive Chair of Dexcom, insider reporter.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DXCM insider trading history →

Related articles

SEP 26
$DXCMMed

DexCom (DXCM) Tests Its Execution Story After Expanding Its CFO Role

DexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.

simplywall.st2 min
SEP 19
$DXCMLow

Did COO Appointment Just Shift DexCom (DXCM) Investment Narrative?

DexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.

simplywall.st2 min
SEP 17
$DXCMLow

DexCom (DXCM) Reshuffles Leadership, Is The Stock Fully Valued?

DexCom (DXCM) promoted CFO Jereme Sylvain to CFO and COO, added Glenn S. Boehnlein to its board. The stock trades at $87.93, up 21.33% over 90 days and 32.15% year-to-date. Analysts estimate fair value at $94.12, with growth driven by expanded insurance coverage and global market penetration. The company trades at a P/E of 33.2x, above sector and peer averages.

simplywall.st2 min
SEP 15
$DXCMMed

Dexcom CFO to expand into COO role

Dexcom's CFO, Jereme Sylvain, will also take on the role of COO, overseeing global operations and quality teams. The move comes as the company develops its G8 continuous glucose monitor and expands its Stelo wearable. Previous COO Jake Leach became CEO in January.

massdevice.com2 min
SEP 14
$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min